Curis Inc (CRIS) Stock Price, Quote & News

Company Profile

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 503 6500

Website: www.curis.com

Address:

Building C, Suite 500 128 Spring Street, Lexington, United States

LodiDodiWeLikesToParty Jul. 12 at 12:03 AM

$CRIS If my heart monitor looked like this, I would have been declared dead a long time ago.

0 · Reply

Topzero Jul. 11 at 7:42 PM

$CRIS They sold more than 650,000 shares today; this is evidence that they will proceed with a stock split. The best way is to escape. 🚀🚀

0 · Reply

Yodalay Jul. 11 at 3:12 PM

$CRIS Huge volume this morning. Funny how news makes it over the wall a few days before we hear about it.

2 · Reply

Topzero Jul. 11 at 3:11 PM

$CRIS The escape from this stock is the best thing—it’s terrifying. I expect a mass exodus from the company.

0 · Reply

View2021 Jul. 10 at 5:32 PM

$CRIS building position This will Make a run to $5

0 · Reply

BallWasher69 Jul. 10 at 4:01 PM

$CRIS feeling like the next time we get any meaningful update will be in 1.5 months when they report Q2 financial / corporate update….

0 · Reply

UCD_12dd Jul. 9 at 11:49 PM

$CRIS apathy towards this stock right now. Zzzzzzzzz…

0 · Reply

LodiDodiWeLikesToParty Jul. 7 at 3:24 AM

$CRIS I also have zero faith in this company and have lost thousands by being a long term investor. They will steal your money. I have been invested here for 4 years. Only massive loss. Lies every day. But sure go ahead and invest with these scumbags. See for yourself.

0 · Reply

Topzero Jul. 5 at 8:11 PM

$CRIS Warning! This company is on the verge of collapse, trying to sell everything it owns using investors’ money. Trust me, the company is finished and will vanish within days or a few months after reducing its shares. Don’t be fooled by their sales announcements—they’re just fake names. My advice: beware! The company’s owners are getting rich by exploiting ordinary investors. Stay away from failing stock companies; this is a new era. Take back your rights and don’t let anyone steal your money. Thank you! Kill him

0 · Reply

NickyTwits Jul. 3 at 3:23 PM

$CRIS new corporate deck is out. NHL - “continue enrollment in PCNSL toward potential Conditional approval and Accelerated approval” AML - “With additional funding, next step is a registrational head-to-head vs gilteritinib” The hard truth is that if they continue to dilute and don’t get a partner, or sell assets, all our shares will be worthless.. the next round of dilution will be the tipping point imo

2 · Reply

Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement

May 6, 2025, 6:16 PM EDT - 2 months ago

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

May 6, 2025, 2:40 PM EDT - 2 months ago

Curis, Inc. (CRIS) Q1 2025 Earnings Call Transcript

May 6, 2025, 8:00 AM EDT - 2 months ago

Curis Provides First Quarter 2025 Business Update

Apr 29, 2025, 8:00 AM EDT - 2 months ago

Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

Apr 2, 2025, 4:05 PM EDT - 3 months ago

Curis to Present at Upcoming Healthcare Conference in April

Mar 31, 2025, 9:59 AM EDT - 3 months ago

Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 8:00 AM EDT - 3 months ago

Curis Provides Fourth Quarter 2024 Business Update

Mar 28, 2025, 4:07 PM EDT - 3 months ago

Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

Dec 10, 2024, 8:00 AM EST - 7 months ago

Curis Announces Additional Data from TakeAim Leukemia Study

Nov 14, 2024, 11:02 AM EST - 8 months ago

Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:00 AM EST - 8 months ago

Curis Provides Third Quarter 2024 Business Update

Nov 7, 2024, 8:00 AM EST - 8 months ago

Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

Oct 29, 2024, 6:04 AM EDT - 9 months ago

Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement

Sep 23, 2024, 8:30 AM EDT - 10 months ago

Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer

Sep 17, 2024, 7:30 AM EDT - 10 months ago

Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 4, 2024, 8:00 AM EDT - 11 months ago

Curis to Present at Upcoming Healthcare Conferences in September

Aug 1, 2024, 3:44 PM EDT - 1 year ago

Curis, Inc. (CRIS) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 8:00 AM EDT - 1 year ago

Curis Provides Second Quarter 2024 Financial and Operating Update

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Curis to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Curis to Present at Upcoming Healthcare Conference in July

May 10, 2024, 8:00 AM EDT - 1 year ago

Curis to Present Updated Data from the TakeAim Leukemia Study

May 7, 2024, 8:08 PM EDT - 1 year ago

Curis, Inc. (CRIS) Q1 2024 Earnings Call Transcript

May 7, 2024, 8:00 AM EDT - 1 year ago

Curis Provides First Quarter 2024 Business Update

Apr 30, 2024, 8:00 AM EDT - 1 year ago

Curis to Release First Quarter 2024 Financial Results and Hold Conference Call on May 7, 2024

Apr 4, 2024, 7:30 AM EDT - 1 year ago

Curis to Present at Upcoming Healthcare Conferences in April

Feb 8, 2024, 2:04 PM EST - 1 year ago

Curis, Inc. (CRIS) Q4 2023 Earnings Call Transcript

Feb 8, 2024, 8:00 AM EST - 1 year ago

Curis Provides Fourth Quarter 2023 Business Update

Feb 1, 2024, 8:00 AM EST - 1 year ago

Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024

Dec 12, 2023, 8:00 AM EST - 1 year ago

Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study

Dec 11, 2023, 8:00 AM EST - 1 year ago

Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference

Dec 6, 2023, 8:00 AM EST - 1 year ago

Curis Announces Three Presentations at ASH

Dec 5, 2023, 8:00 AM EST - 1 year ago

Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma

Nov 17, 2023, 9:04 AM EST - 1 year ago

Curis's stock rises as analysts see ‘the next Pharmacyclics'

Nov 2, 2023, 2:32 PM EDT - 1 year ago

Curis, Inc. (CRIS) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 8:00 AM EDT - 1 year ago

Curis Provides Third Quarter 2023 Business Update

Oct 26, 2023, 8:30 AM EDT - 1 year ago

Curis to Release Third Quarter 2023 Financial Results and Hold Conference Call on November 2, 2023

Sep 12, 2023, 8:00 AM EDT - 1 year ago

Curis Announces Date for the 2nd Symposium on IRAK4 in Cancer

Aug 3, 2023, 9:35 PM EDT - 2 years ago

Curis, Inc. (CRIS) Q2 2023 Earnings Call Transcript

Aug 3, 2023, 4:01 PM EDT - 2 years ago

Curis Provides Second Quarter 2023 Business Update

Jul 27, 2023, 6:25 PM EDT - 2 years ago

Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023

Jul 6, 2023, 8:01 AM EDT - 2 years ago

FDA Removes Partial Clinical Hold on TakeAim Leukemia Study RP2D Established at 300 mg BID

Jul 6, 2023, 8:00 AM EDT - 2 years ago

Curis Announces $15.1 Million Registered Direct Offering

May 4, 2023, 9:59 PM EDT - 2 years ago

Curis, Inc. (CRIS) Q1 2023 Earnings Call Transcript

May 4, 2023, 4:01 PM EDT - 2 years ago

Curis Provides First Quarter 2023 Business Update

Apr 27, 2023, 4:01 PM EDT - 2 years ago

Curis to Release First Quarter 2023 Financial Results and Hold Conference Call on May 4, 2023

Mar 13, 2023, 12:22 PM EDT - 2 years ago

Curis, Inc. (CRIS) Q4 2022 Earnings Call Transcript

Mar 13, 2023, 8:00 AM EDT - 2 years ago

Curis Provides Fourth Quarter 2022 Business Update

Mar 8, 2023, 7:09 PM EST - 2 years ago

Curis Reschedules Fourth Quarter 2022 Business Update and Conference Call

LodiDodiWeLikesToParty Jul. 12 at 12:03 AM

$CRIS If my heart monitor looked like this, I would have been declared dead a long time ago.

0 · Reply

Topzero Jul. 11 at 7:42 PM

$CRIS They sold more than 650,000 shares today; this is evidence that they will proceed with a stock split. The best way is to escape. 🚀🚀

0 · Reply

Yodalay Jul. 11 at 3:12 PM

$CRIS Huge volume this morning. Funny how news makes it over the wall a few days before we hear about it.

2 · Reply

Topzero Jul. 11 at 3:11 PM

$CRIS The escape from this stock is the best thing—it’s terrifying. I expect a mass exodus from the company.

0 · Reply

View2021 Jul. 10 at 5:32 PM

$CRIS building position This will Make a run to $5

0 · Reply

BallWasher69 Jul. 10 at 4:01 PM

$CRIS feeling like the next time we get any meaningful update will be in 1.5 months when they report Q2 financial / corporate update….

0 · Reply

UCD_12dd Jul. 9 at 11:49 PM

$CRIS apathy towards this stock right now. Zzzzzzzzz…

0 · Reply

LodiDodiWeLikesToParty Jul. 7 at 3:24 AM

0 · Reply

Topzero Jul. 5 at 8:11 PM

0 · Reply

NickyTwits Jul. 3 at 3:23 PM

2 · Reply

ELI666 Jul. 3 at 2:13 PM

$CRIS Stop shorting stocks. That way you won't leave dumb comments on the wall.

1 · Reply

ELI666 Jul. 3 at 2:08 PM

$CRIS ✅ 1$ S00N!! $MLGO $LRHC

0 · Reply

LodiDodiWeLikesToParty Jul. 3 at 11:37 AM

$CRIS Neverending trials and data. This is the gen z of drugs and will never launch. Just another 40 year old living with their parents with no job is all this will be.

0 · Reply

ELI666 Jul. 3 at 5:59 AM

$CRIS $GRYP $MOGO 🚨 CRIS is Getting Ready to Fly! 🚨 After reporting improved Q1 results and securing analyst support with a $17 price target, Curis (CRIS) is shaping up for a breakout. 🧬 The company is advancing promising clinical trials 💰 Dilution risk is low for now (warrants priced at $2.20 while the stock is at $1.75) 📈 Oversold after a 19% dip – setup for a technical rebound 🧪 Strong pipeline + new leadership = bullish momentum This is not just another biotech — this is a recovery story in the making. Watch CRIS today. The move could be explosive.

1 · Reply

GhostAlphaTrading Jul. 2 at 11:42 PM

$CRIS 👻

0 · Reply

LodiDodiWeLikesToParty Jul. 2 at 9:20 PM

$CRIS go ahead and put this stock out of its misery

0 · Reply

_www_larval_com_ Jul. 2 at 3:07 PM

$CRIS has turned 4% higher to -11% (~789Kv) in the last few minutes, follow for more volatility.

0 · Reply

NickyTwits Jul. 2 at 1:47 PM

$CRIS not surprising. I’m not too upset with the size of the raise (relatively small) and it gets them to their next milestone. More concerned with the fact that this confirms their struggles finding a partner..

2 · Reply

Esau815 Jul. 2 at 1:38 PM

$SANA Take a look at $CRIS today. Stock getting slaughtered due to dilution. $CRIS has potentially great science but lousy management but the concept is the same. Raising $ in this environment is difficult. Let's just agree that $SANA is sitting on potentially great science. Let's disagree that the road to get to the finish line is going to be easy.

0 · Reply

Yodalay Jul. 2 at 1:33 PM

$CRIS Unfortunate, but not a surprise. Picked up a few at $1.55

0 · Reply

RedDrumification Jul. 2 at 1:33 PM

$CRIS https://www.prnewswire.com/news-releases/curis-announces-7-0-million-registered-direct-and-concurrent-private-placement-302496802.html Funding $7M to apparently get them through early 2026

0 · Reply

UCD_12dd Jul. 2 at 1:03 PM

$CRIS WTF??

1 · Reply

Market Cap	20.19M
Revenue (ttm)	10.91M
Net Income (ttm)	-43.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-397.71%
Debt to Equity Ratio	0.00

Volume	701,700
Avg Vol	129,782
Day's Range	N/A - N/A
Shares Out	10.46M
Stochastic %K	34%
Beta	3.60
Analysts	Strong Sell
Price Target	$17.00